CCI-779 in Treating Patients With Metastatic Melanoma
A Phase II Study Of CCI-779 (NSC 683864) In Metastatic Melanoma
A Phase II Study Of CCI-779 (NSC 683864) In Metastatic Melanoma
Sponsor study identifier
Secondary identifiers
interventional
N/A
2 countries
21
Study Start
June 2001
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2005
Actual (reported)Study Completion
September 2005
Actual (reported)RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CCI-779 in treating patients who have metastatic melanoma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2005
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2001
Date type not reportedThis date has not been verified as actual or estimated.
August 10, 2001
Actual (reported)January 27, 2003
Actual (reported)September 2005
Actual (reported)September 2005
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
City of Hope Comprehensive Cancer Center
Duarte, California, 91010-0269, United States
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90089, United States
City of Hope Medical Group
Pasadena, California, 91105, United States
University of California Davis Cancer Center
Sacramento, California, 95817, United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470, United States
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640, United States
Decatur Memorial Hospital Cancer Care Institute
Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005 Sep 1;104(5):1045-8. doi: 10.1002/cncr.21265.
Kim A. Margolin, MD
City of Hope Medical Center
First Submitted
August 10, 2001
First Posted
January 27, 2003
Study Start
June 2001
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2005
Actual (reported)Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Decatur, Illinois, 62526, United States
Evanston Northwestern Health Care - Evanston Hospital
Evanston, Illinois, 60201, United States
Ingalls Memorial Hospital
Harvey, Illinois, 60426, United States
LaGrange Memorial Hospital
LaGrange, Illinois, 60525, United States
Loyola University Medical Center
Maywood, Illinois, 60153, United States
Oncology/Hematology Associates of Central Illinois, P.C.
Peoria, Illinois, 61602, United States
Central Illinois Hematology Oncology Center
Springfield, Illinois, 62701, United States
Fort Wayne Medical Oncology and Hematology, Incorporated
Fort Wayne, Indiana, 46885-5099, United States
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601, United States
North Shore University Hospital
Manhasset, New York, 11030, United States
Weill Medical College of Cornell University
New York, New York, 10021, United States
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104-4283, United States
Cancer Care Ontario-Hamilton Regional Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, N6A 4L6, Canada
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
Study Completion
September 2005
Actual (reported)Last Updated
June 8, 2015
Record last verified: 2015-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: